crispr patent landscape - ipstudies · eu horizon2020 expert on innovation in smes 2013-2015 •...

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017 IPStudies SARL

CRISPRPATENTLANDSCAPEAugust2017

Intangibleassets deserve closer scrutiny

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

Copyright

• Unless otherwise specified, all content included on this document, such astext, graphics, logos, button icons, images, audio and video clips, digitaldownloads, data compilations, and software, including but not limited toIPStudies surveys, is the property of IPStudies SARL and protected byinternational copyright laws.

• You agree not to copy, reproduce, duplicate, sell, resell, or exploit for anycommercial purposes, any portion of this content.

• You may not re-use and/or extract part of this content outside of your legalentity, institutional or corporate environment without IPStudies’s expressconsent in writing.

2


Ourteam

3

CorinneLEBUHAN,PhDICTExpertIPStrategy&Management

• FundedIPStudiesin2010tohelpSwiss&EUhigh-techSMEsdevelopandexecutetheirIPvaluationplansusingthelatestpatentanalyticstoolsandtrends

• 15yearsexperienceinIPstrategyandmanagement– formerVPKnowledgeManagementofNagravision-Kudelski Group,inchargewithpatents(200families),standards,R&Dcollaborations,licensingandtechnicalpublicationsportfolios

• TeachesinternationallicensingpracticesandIPstrategyatIEEPI–EUHorizon2020expertonInnovationinSMEs2013-2015

• ICTTechnologyExpertforvariouslicensingfacilitatorsandaggregatorsinFrance,GermanyandtheUS

• Universitypostgraduateinmanagementofinnovationandintellectualproperty(UniversityofStrasbourg,2008),PhDinCommunicationsScience(EPFL,1998),MsC inElectricalEngineering(INSARennes,1994)

• ExperiencedwithPatbase,EPO/RegisterPlus,USPTO/PAIR

• InternationalnetworkofIPpractitionersandlicensingmanagers-MemberLES,IEEE,AROPI,AAIEEPI

FabienPALAZZOLI,PhDLifeSciencesExpertPatentAnalysis&Landscapes

• JoinedIPStudies in2013todeveloptheIPanalyticsofferinginlifesciences&biotechnology

• 9+yearsexperienceintechnologytransfers,patentmapping/landscapingandFTO-drivenresearchintelligencefortheFrenchpublicsectorandbiotechSMEs- formerIPanalyticssalesmanagerforFISTSA,theCNRStechnologytransferoffice

• Author/co-authorof18scientificandtechnicalpublications/communications,aswellasonebookchapter

• Lifesciencespatentanalystforvariousbiotech/medtech SMEsinSwitzerlandandinEurope

• PhDinLifeSciences(Exploitationofpatentinformationinapublicresearchlaboratory:identificationoftechnologicalnichesinbioproduction andgenetherapy,UniversityofTours,2011),MsC inBiotechnologyandLaw(UniversityofTours,2007)

• ExperiencedwithOrbit,Patbase,Intellixir,patentofficesdatabases

• Internationalnetworkofpatentinformationanalysts


Tableofcontents

4

• Methodology

• OveralltrendsoftheCRISPRpatentdatabase• Temporaldistributionofpatentfilings(2002-2017)• Temporaldistributionofpatentfilingsbytypeofplayers(2002-2017)• Worldmapofpriorityfilings• Temporaldistributionofpriorityfilings(2002-2017)• Worldmapofpatentextensions• Mainpatentapplicants/assigneesandtemporaldistributionoftheirfilings• Co-filingsbetweenapplicants/assignees

• BreakdownoftheCRISPRpatentdatabase• BreakdownbyClaimcoverageofpatentfamilies

• Breakdownofthepatentportfolio• Temporaldistributionoffilings• Positioningofapplicants/assignees

• BreakdownbyComponents• Breakdownofthepatentportfolio• Temporaldistributionoffilings• Positioningoftheapplicants/assignees

• BreakdownbyChimericproteins• Breakdownofthepatentportfolio• Temporaldistributionoffilings• Positioningofapplicants/assignees

• Mainforwardcitedpatentfamilies• Appendice1– Licensingannouncements• Appendice2– Affiliationmappingofplayerspresentinthepatentlandscape


Temporaldistributionofpatentfilingsbytypeofplayers(2002-2017)

Ø 1043 filings by institutional applicants/assignees (60.5%),Ø 553 filings by industrial applicants/assignees (32.1%),Ø 74 filings by individual inventors (4.3%),Ø 57 co-filings between industrial applicants/assignees and institutional applicants/assignees (3.3%).Ø The years 2016 and 2017 are not complete due to the delay of publication of 18 months.

1724patentfamilies


Mainpatentapplicants/assignees (≥12patentfamilies)

Institutional applicant/assignee

Industrial applicant/assignee

Ø Affiliates & subsidiaries have been gathered under their parent company (Danisco with DuPont…). Co-filings arecounted for each co-owner: a patent application co-filed between the MIT, the Harvard University and theBroad Institute is counted once for each of this applicant.

Ø The patent portfolio of DuPont comprises historical patent families on CRISPR sequences dealing with the typingof bacterial strains, cultures with improved phage resistance and applications for preparing food.


Temporaldistributionoffilingsofmainapplicants/assignees(≥12patentfamilies)

7


Co-filingsbetweenapplicants/assignees(≥2co-filings)

8

Number ofpatentfamiliesintheportfolio

Co-filing(s)betweenthetwo applicants

Ø The co-filing map shows the co-filings between applicants/assignees. The same type of link can be found whenan assignment occurred between two players, giving the historical applicants as well as the new owners.


BreakdownoftheCRISPRpatentdatabase(1)

Ø A patent family can be classified in several categories (e.g. ‘Genome Editing’ and ‘Therapeutic application’and ‘Human cell-subject’ and ‘CRISPR-Cas system’…).

• Genomeediting

• Transcriptional-epigeneticregulation

• Otherapplication

• Therapeutics-Diagnostics

• Bioproduction

• Drugscreening

• Modifiedcell

• Modifiedanimal

• Modifiedplant

Applications

• Humancell-subjet

• Mammaliancell-organism

• Otheranimalcell-organism

• Plantcell-organism

• Fungi-algae-yeast

• Eukaryoticcell-organism

• Prokaryoticcell

• Otherorganism

• Undefinedcell-organism

Cells/Organisms

• Nuclease

• ZFNuclease-ZFP

• Meganuclease

• TALENuclease-TALEP

• gRNA-guidesequence

• Cas-CRISPRenzyme

• CRISPRsystem

• Otherchimericprotein

• Vector-Delivery

• CRISPRsequence

‘Moleculartools’

‘CLAIMCOVERAGE’

The1724patentfamilies havebeenmanually classified


BreakdownoftheCRISPRpatentdatabase(2)

Ø A patent family can be classified in several categories (e.g. ‘Genome Editing’ and ‘Therapeutic application’and ‘Human cell-subject’ and ‘CRISPR-Cas system’…).

COMPONENTS CHIMERICPROTEINS

Chimericnucleases

• Undefinednucleases

• ZFNucleases

• Meganucleases

• TALENucleases

• RNA-GuidedNucleases

• Otherchimericnucleases

Otherchimericproteins

The1724patentfamilies havebeenmanually classified

• Cas-CRISPRenzyme

• MutatedCas - nickase

• dCas

• Cas9

• mutatedCas9- nickase

• dCas9

• OtherCas

• OthermutatedCas

• Cpf1-mutatedCpf1

• gRNA

• sgRNA-chiRNA

• crRNA

• tracrRNA

• Nuclease-Nickase

• Meganuclease

• Integrase

• Recombinase

• Repressor-Activator

• Acetyltransferase

• Deacetylase

• Methyltransferase

• Demethylase

• Kinase

• Othercatalyticdomain

• Undefinedcatalyticdomain


BreakdownbyClaimcoverageofpatentfamiliesBreakdownofthepatentportfolio

11

Applications Cell /Organism ‘Covered molecular tools’


BreakdownbyClaimcoverageofpatentfamiliesPositioningofmainapplicants/assignees(≥12patentfamilies)

12


BreakdownbyComponentsBreakdownofthepatentportfolio

13


BreakdownbyComponentsPositioningofmainapplicants/assignees(≥12patentfamilies)

14


BreakdownbyChimericproteinsBreakdownofthepatentportfolio

15

Nucleases including chimeric nucleases Other chimeric proteins


BreakdownbyChimericproteinsPositioningofmainapplicants/assignees(≥12patentfamilies)

16


Licenseannouncements(samplepage4)

Licensor Scope Licensee Date

Toolgen

Worldwidelicense&sublicensesrightsforresearchapplicationsincludingthedevelopmentandsaleofreagents,celllines,andanimalmodels,aswellasrightsforhighthroughputscreening,diagnostics,andbioproduction.ToolGen retainsitsrightsinbroadareasincludinghighthroughputscreening,diagnostics,bioproduction,plantbiotechnologyandgene/celltherapy.

ThermoFisher Scientific 2015/03

VilniusUniversityExclusiverights tothe Cas9-mediatedgenomeeditingintellectualpropertyownedbyVilniusUniversityforallcommercialuses,includinginagriculture.

DuPont 2015/06

UniversityofMinnesota

Exclusiveworldwiderights toanAAVgenetherapyandintellectualpropertyfromtheUniversityofMinnesotatotreatpatientswithFanconianemia(FA)disorderandotherrareblooddiseasesusingtheCRISPR/cas9technology platform.

AbeonaTherapeuticsInc 2015/06

CaribouBiosciencesDupont(incl.VilniusUniversity)

Multi-faceted agreementincludes thecross-licensing ofkeyIP,aresearch collaboration,andfinancial investments byDuPont inCariboutodevelopandutilizeCRISPR-Castechnologyforproductdevelopmentinmultiplefieldsincludinghumanandanimaltherapeutics,diagnostics,industrialbiotechnology,researchtools,andcertainagriculturesegments.TheDuPontlicensetoCaribouincludesrightstotheCas9-mediatedgenomeediting IPownedbyVilniusUniversityandexclusivelylicensedtoDuPont inmultiplefields and exclusiveaccess intheresearch tools field.

CaribouBiosciencesDuPont(incl.VilniusUniversity)

2015/10

CrisprTherapeutics

$105millionupfront—$75millionincash,$30millionequityinvestment- futuredevelopment,regulatoryandsalesmilestonesofupto$420millionforeachofuptosixCRISPR-Cas9-basedtreatmentsforwhichVertexhasagreedtolicenseexclusivedevelopmentrights (incl.cystic fibrosis).Royaltiesonfuturesales.

Vertex 2015/10


Furtheranalyticsforyourspecificneedswiththeonlinedatabase

• Zoomonpatentportfoliosofspecificapplicants

• Zoomonpatentsfiledinacountry/region(US,EP,CN…),withinatimeperiod

• Zoomonpatentscoveringanapplication,adedicatedtechnology,aspecificationorafunctionalsubset

• Linktoonlinepatentofficeregisterstoreviewlatestlegalstatus

18


Accesstotheinteractive“navigate,zoom,clickandshowpatent”database

19

4

1

2

3


Order

20

This is only a sample report with partial data. Our fulloffer includes:• ananalysisofthepatentlandscape,covering1724patentfamilies,worldwide• asynthesisofIPstrategyfindings,tovisualizekeytrendsintermsofpatentapplicants,collaborationnetworks,competitortechnologypositioning,keyinventorsandR&Dwhitespacesoutofthelandscape• anon-lineaccesstothe1724patentfamiliesset,soyoucanvisualize,navigate,focusandextractthemostrelevantpatentdataaccordingtoyourspecificneeds.

[email protected]+41797875746

crispr patent landscape - ipstudies · eu horizon2020 expert on innovation in smes 2013-2015 •...

Documents